Trial Profile

Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AKS-452 (Primary) ; AKS-452 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms ACT

Most Recent Events

23 Feb 2023 Results (n=52) assessing the safety and immunogenicity of AKS-452 in healthy adults, published in the Vaccine.
04 Apr 2022 Status changed from active, no longer recruiting to completed.
08 Feb 2022 According to an Akston Biosciences media release, interim data published in Vaccine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com